CME/CE - Prova Education

Episodes 1-16 of 196

CME/CE Meeting
Advances in the Treatment and Management of MASH: More Options, More Decisions
October 26, 2024
Philadelphia, Pennsylvania
1.50 credits Learn more
Advances in the Treatment and Management of MASH: More Options, More Decisions
Advances in the Treatment and Management of MASH: More Options, More Decisions
CME/CE Live Broadcast
Advances in the Treatment and Management of MASH: More Options, More Decisions
October 26, 2024
08:00 PM - 09:30 PM EDT
1.50 credits Learn more
CME/CE Meeting
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient
November 17, 2024
San Diego, California
1.50 credits Learn more
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient
CME/CE Live Broadcast
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient
November 17, 2024
12:30 PM - 02:00 PM PST
1.50 credits Learn more
Pediatric Narcolepsy: Timely Diagnosis, Treatment, and Outcome Optimization
Pediatric Narcolepsy: Timely Diagnosis, Treatment, and Outcome Optimization
CME/CE
Pediatric Narcolepsy: Timely Diagnosis, Treatment, and Outcome Optimization
1.00 credit
- Anne Marie Morse, DO, FAASM
1.00 credit
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
MinuteCE®
Frontline Fixed-Duration Therapy in CLL: Improving Outcomes and Tolerability
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Risk-Stratification in Newly Diagnosed CLL
Risk-Stratification in Newly Diagnosed CLL
MinuteCE®
Risk-Stratification in Newly Diagnosed CLL
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Mutational Testing to Guide Therapy in CLL: Why and When
Mutational Testing to Guide Therapy in CLL: Why and When
MinuteCE®
Mutational Testing to Guide Therapy in CLL: Why and When
1.25 program credits
- Talha Munir, PhD
1.25 program credits
MinuteCE®
Fixed-Duration: A Patient-Captivating Standard of Care in CLL
1.25 credits 10 episodes
- Talha Munir, PhD
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 credits 10 episodes
MRD Testing to Guide Treatment Considerations in CLL
MRD Testing to Guide Treatment Considerations in CLL
MinuteCE®
MRD Testing to Guide Treatment Considerations in CLL
1.25 program credits
- Talha Munir, PhD
1.25 program credits
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
MinuteCE®
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
MinuteCE®
The Challenge of BCL-2 Resistance in CLL: Treatment Strategies and Emerging Therapies
1.25 program credits
- Thomas Kipps, MD, PhD
1.25 program credits
Combination Therapy for CLL: What Evidence Do We Have?
Combination Therapy for CLL: What Evidence Do We Have?
MinuteCE®
Combination Therapy for CLL: What Evidence Do We Have?
1.25 program credits
- William Wierda, MD, PhD
1.25 program credits
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
MinuteCE®
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
MinuteCE®
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
MinuteCE®
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
1.25 program credits
- Thomas Kipps, MD, PhD
- William Wierda, MD, PhD
1.25 program credits

Prev
1
2
3
…
12
13
Next

1/6